. Different epigenetic processes that may lead to physically and/or functionally variable forms of protein isoforms from a single gene sequence. Reprinted with permission from reference 2.
rectly from as little as a microliter of serum (7) . Furthermore, archival air-dried cytologic smears obtained by fine-needle aspiration cytology can be analyzed, as shown by Fetsch et al (8) . The sample is applied to a chip containing up to 24 distinct regions on an aluminum support (i.e., the ProteinChip array). The aluminum surface is coated according to interest with one of a variety of substances that have a desired chemical or electrical characteristic (hydrophobic vs hydrophilic, cationic vs anionic). Alternatively, the chip surface could be coated with a specific antibody or protein receptor targeting a protein group of interest. These coated affinity surfaces capture proteins on the basis of their physical, electrochemical, or antigenic qualities.
The chip is then exposed to an ultraviolet nitrogen laser beam that dislodges the captured protein (desorption), transforming it into a gaseous ion (ionization) by protonization. The gaseous ions are accelerated in an electric field and "fly" to hit a detector. It is the variation in TOF that allows for separation of the different protein components originally captured on the chip surface. The TOF variation is based on the mass/charge ratio of each peptide. Peptides with a higher mass take a longer time to fly to the detector. With the aid of computer analysis, results are displayed as peaks representing the different peptide components of a given sample.
By characterizing proteomic "fingerprints" associated with a particular type of tumor, it is possible to identify an unknown tumor sample that matches a previously defined fingerprint. This can be done on the basis of the "peaks" pattern even without actually knowing which protein each peak represents.
Expressional proteomics
Among the several disciplines already emerging within the field of proteomics, expressional proteomics could lend itself most readily to molecular diagnostic applications. In 2002, a National Institutes of Health group led by a pathologist, Lance Liotta, MD, published their results of what many now consider the sentinel study in the field of expressional proteomics (9) . The objective of their study was to identify a serum proteomic pattern that would help in the early detection of ovarian carcinoma. Given the fact that currently available serologic markers such as CA125 fail to detect up to 50% of cases of early stage ovarian carcinoma, a highly sensitive, noninvasive screening assay will be invaluable for such a devastating disease.
Using data obtained by mass spectrometry analysis of 100 samples, a "training set" composed of 50 serum samples from patients with benign ovarian cysts and 50 samples from ovarian carcinoma patients, the National Institutes of Health group was able to develop an algorithm of differential proteomic patterns for the two groups. They next tested their algorithm on a masked 116-sample testing set composed of 50 serum samples from ovarian carcinoma patients and 66 controls. Their astonishing results are summarized in Table 1 . The newly developed proteomic-based algorithm was able to correctly identify all 50 patients with ovarian carcinoma, including all 18 patients with stage I disease. Several similar studies have followed, illustrating the great potential of proteomic analysis for early detection of neoplasia. In a study conducted at Memorial Sloan-Kettering Cancer Center, Villanueva et al (10) were able to demonstrate a proteomic fingerprint pattern for glioblastoma multiforme using serum Normal contralateral Breast cancer mass spectrometry analysis followed by hierarchical clustering data analysis (Figure 3 ) similar to that widely used in DNA chip technology. The latter is based on "clustering" cases according to similarity in proteomic (or genomic) fingerprint pattern, resulting in a branched-tree-like depiction in which most similar cases are listed in neighboring branches. In two other intriguing studies, REF, the proteomic breast cancer "fingerprint," was identified in nipple aspiration fluids analyzed by two-dimensional gel electrophoresis (11) (Figure 4 ) or SELDI-TOF mass spectrometry (4).
CLINICAL APPLICATIONS OF MOLECULAR DIAGNOSTICS IN HEMATOPATHOLOGY Immunoglobulin heavy-chain gene and T-cell receptor gene rearrangement
In the appropriate setting, gene rearrangement studies are a powerful tool to establish a diagnosis of lymphoma. The test can be invaluable by establishing evidence of monoclonality in a morphologically suspect lymphoid infiltrate.
Currently, gene rearrangement studies are most commonly performed using a polymerase chain reaction (PCR)-based assay that exploits physiologic genetic rearrangements (deletions) occurring during B-and T-cell lymphocyte differentiation in response to antigen stimulation. As illustrated in Figure 5a , when B lymphocytes undergo rearrangement of their immunoglobulin heavy-chain (IgH) gene, portions of the gene sequence are deleted, leading to formation of a shorter new sequence that can be flanked by a set of consensus PCR primers (complementary nucleic acid sequences) that allow for amplification of the new sequence. A neoplastic (clonal) lymphocytic population shares an IgH gene sequence identical in size and composition. This leads to a PCR product homogenous in both size and electric charge that electrophoretically migrates as a single band when run on an agarose gel (Figure 5b) . The PCR product migrates as a single peak when analyzed using a capillary electrophoresisequipped sequencing instrument (Figure 6 ). This assay gives today's pathologist a powerful tool that can add an additional level of diagnostic confidence when faced with a biopsy (fresh or paraffin-embedded archival) containing morphologically suspect lymphoid cells.
However, the need to integrate clinical data with findings on histology, flow cytometry, and gene rearrangement studies cannot be overemphasized. Documenting clonality does not always equate with a diagnosis of malignancy. Certain reactive inflammatory conditions such as autoimmune processes and infectious conditions (e.g., hepatitis C, Helicobacter pylori) (12) can contain a clonal B-or T-cell population detectable by gene rearrangement studies. Finally, it is wise to remember that the sensitivity of a gene rearrangement assay can vary from 40% to 80% depending on the technique used by a specific laboratory (13).
Molecular cytogenetics
Molecular cytogenetics is defined as the characterization of chromosomal abnormalities using molecular techniques such as PCR and reverse-transcription PCR (RT-PCR), Southern blot, or fluorescence in situ hybridization (FISH). FISH offers the added advantage of being applicable to both metaphase and interphase targets while preserving crucial morphologic and topographic findings. These techniques lend themselves to identification of chromosomal translocations, deletions, inversions, and numerical aberrations.
The essential role now played by molecular cytogenetics in the diagnosis, monitoring, and management of chronic myelogenous leukemia (CML) offers a great paradigm for future integration of molecular diagnostics in the management of other neoplastic diseases.
The characteristic translocation of CML, i.e., BCR-ABL/ t(9;22)(q34;q11.2), results in the formation of a chimeric (fusion) gene (BCR-ABL, or the Philadelphia chromosome) with a tyrosine kinase function continuously promoting proliferation in affected leukocytes (14) . The BCR-ABL mRNA transcripts can be detected and quantified in blood samples of new patients by using real-time RT-PCR. The latter not only helps establish the diagnosis of CML but offers a baseline measurement for future monitoring of the patient's response to targeted therapy with imatinib mesylate (Gleevec). BCR-ABL translocation can also be detected by FISH (15) . Several types of probes are available for that purpose, as shown in Figure 7 . Furthermore, FISH analysis for other markers in CML, such as trisomy 8 (Figure 8a) (16, 17) and chromosome 9q34 deletion (18, 19) (Figure 8b ), can help detect clonal evolution and the need for more aggressive therapy ( Figure 9) . A rapidly growing number of assays are now offered to help manage several hematologic neoplasms. Table 2 includes some that are more commonly used. These tests are of great clinical utility in helping to predict prognosis (e.g., trisomy 12 in chronic lymphocytic leukemia), select appropriate therapy (e.g., promyelocytic leukemia-retinoic acid receptor α [PML-RARA] in acute myelogenous leukemia-M5), or monitor response to treatment (BCR-ABL/t(9:22) in CML). Molecular cytogenetic testing has the advantage of a faster turnaround time and at times superior sensitivity compared with conventional cell culture and Gbanding-based cytogenetic tests. Tel-AML1 translocation in acute lymphoblastic leukemia and inversion 16 in acute myelogenous leukemia-M4Eo are examples of "cryptic" abnormalities that could not be detected by conventional cytogenetic techniques (20, 24) .
CHIMERISM ENGRAFTMENT STUDIES
Chimerism analysis after bone marrow or stem cell transplantation offers an objective, quantitative measure for monitoring engraftment of donor cell populations in the new host. Engraftment assays exploit differences in genetic markers between donor and recipient cells. Short tandem repeats (STR), or microsatellites, are noncoding DNA loci, each composed of repeated units of 2 to 7 nucleotides (usually dinucleotides or trinucleotides). STR are polymorphous markers that vary in the number of repeats within a specific STR locus. Each individual inherits one paternal and one maternal allele of a specific STR locus, leading to further diversity in terms of his or her STR pattern (Figure 10 ).
PCR analysis of STR loci highlights differences among pretransplant donor and recipient leukocytes. Loci that are different between donor and recipient are considered informative and are subsequently monitored after transplantation to determine engraftment status (Figure 11 ) (26) (27) (28) (29) . Recently, posttransplantation chimerism analysis has been used in the assessment of minimal residual disease (MRD). Since STR analysis by PCR has a sensitivity of only 1% to 5% for the minor population in a chimeric sample, an additional step of cell sorting is performed that Figure 11 . Evaluation of engraftment by short tandem repeat analysis after bone marrow transplantation. Peripheral blood leukocyte subpopulations were analyzed (rows 3, 4, 5, 6). Arrows indicate informative peaks that distinguish donor and recipient identity; these peaks can be useful in evaluating the source of leukocytes in blood samples after transplantation. Figure 10 . Schematic of short tandem repeat markers. In this heterozygous example, differences in the number of CA repeats (6 vs 9) between the two alleles result in two distinct polymerase chain reaction peaks by capillary electrophoresis. These peaks can be used as genetic markers of this individual identity.
specifically selects for the neoplastic (e.g., leukemic) cells; this increases the sensitivity of the STR assay, thus allowing evaluation of MRD after bone marrow transplantation. Early detection of the presence of MRD allows for early intervention strategies, such as decreased immunosuppression or donor lymphocyte infusion, that target the neoplastic population (graft-vs-leukemia effect) (27, 28) .
Finally, (X,Y) FISH analysis can be used to evaluate engraftment in cases of gender-mismatch transplantation (27) . This technique is based on the labeling (by painting or centromeric probes) of the X and Y chromosomes in leukocytes after bone marrow transplantation. Cells can thus be easily assigned a donor or recipient genetic origin (27) . (X,Y) FISH-based chimerism analysis can be instrumental in cases of across-gender bone marrow transplant in which pretransplantation donor or recipient samples are not readily available for STR analysis.
CONCLUSION
Proteomics holds great promise in providing pathologists and clinicians with new sensitive, noninvasive tools for early detection of neoplasms such as ovarian carcinoma. The application of molecular diagnostics in hematologic neoplasms is a model for its application in the wider arena of solid tumors. Currently, gene rearrangement studies, molecular cytogenetics, and chimerism analysis are providing pathologists and oncologists with highly accurate tools to successfully navigate the difficult diagnostic and management pathways in hemato-oncology.
